<DOC>
	<DOCNO>NCT01594437</DOCNO>
	<brief_summary>The purpose study compare safety profile healthy adult volunteer single multiple intravenous administration TCN-202 compare placebo .</brief_summary>
	<brief_title>Safety Study Human Anti-Cytomegalovirus Monoclonal Antibody</brief_title>
	<detailed_description>Human cytomegalovirus ( HCMV ) disease remain unmet medical need : In US , estimate prevalence congenital HCMV infection ~1 % one leading cause permanent hearing loss neurological deficit child . In immunocompromised individual transplant recipient cause serious life-threatening disease may significantly increase risk graft rejection . As exist therapy HCMV serious side effect , remain medical need safe effective treatment HCMV disease .</detailed_description>
	<mesh_term>Cytomegalovirus Infections</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<mesh_term>Immunoglobulins</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>Healthy adult volunteer Normal lab test Prior treatment monoclonal antibody</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>March 2014</verification_date>
	<keyword>Cytomegalovirus</keyword>
	<keyword>Monoclonal antibody</keyword>
</DOC>